research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
In response to doubts about the lack of nuclear products, cold fusion researchers have tried to capture and measure nuclear products correlated with excess heat. Considerable attention has been given to measuring 4He production. However, the reported levels are very near to background, so contamination by trace amounts of helium normally present in the air cannot be ruled out. In the report presented to the DOE in 2004, the reviewers' opinion was divided on the evidence for 4He, with the most negative reviews concluding that although the amounts detected were above background levels, they were very close to them and therefore could be caused by contamination from air. One of the main criticisms of cold fusion was that deuteron-deuteron fusion into helium was expected to result in the production of gamma rays—which were not observed and were not observed in subsequent cold fusion experiments. Cold fusion researchers have since claimed to find X-rays, helium, neutrons and nuclear transmutations. Some researchers also claim to have found them using only light water and nickel cathodes. The 2004 DOE panel expressed concerns about the poor quality of the theoretical framework cold fusion proponents presented to account for the lack of gamma rays.
The first stable human-animal chimeras to actually exist were first created by Shanghai Second Medical University scientists in 2003, the result of having fused human cells with rabbit eggs. In 2017 researchers led by the Salk Institute published in Cell experiments using CRISPR-Cas9 gene editing to aid in blastocyst complementation with pluripotent stem cells in various mammals. This included a human-pig chimera reported to have 0.001% human cells, with the remaining cells pig. The embryo consisted mostly pig cells and some human cells. Scientists stated that they hope to use this technology to address the shortage of donor organs. In 2021, a human-monkey chimera was created as a joint project between the Salk Institute in the US and Kunming University in China and published in the journal Cell. This involved injecting human stem cells into monkey embryos. The embryos were only allowed to grow for a few days, but the study demonstrated that some of these embryos still had human stem cells surviving at the end of the experiments. Because humans are more closely related to monkeys than other animals, it means there is more chance of the chimeric embryos surviving for longer periods so that organs can develop. The project has opened up possibilities into organ transplantation as well as ethical concerns particularly concerning human brain development in primates.
In medicine (hematology), bleeding diathesis is an unusual susceptibility to bleed (hemorrhage) mostly due to hypocoagulability (a condition of irregular and slow blood clotting), in turn caused by a coagulopathy (a defect in the system of coagulation). Therefore, this may result in the reduction of platelets being produced and leads to excessive bleeding. Several types of coagulopathy are distinguished, ranging from mild to lethal. Coagulopathy can be caused by thinning of the skin (Cushing's syndrome), such that the skin is weakened and is bruised easily and frequently without any trauma or injury to the body. Also, coagulopathy can be contributed by impaired wound healing or impaired clot formation.
=== Ecologic system of soil decontamination === The Altran Foundation jury awarded the first prize 2001 to Julien Troquet, a young research engineer and founder of the start-up company Biobasic Environnement. His project consists in developing a decontamination process for soil using bioremediation. This process allows for a complete decontamination using a gentle "alternative" method, so the excavation of the site is not necessary and the ecosystem is preserved. It is five times less expensive than competing techniques and can also be used on many different types of pollution.
Sources: en.wikipedia.org
===== MeSH D08.811.399.475 – intramolecular oxidoreductases (EC 5.3) ===== MeSH D08.811.399.475.200 – aldose-ketose isomerases MeSH D08.811.399.475.200.174 – autocrine motility factor MeSH D08.811.399.475.200.350 – glucose-6-phosphate isomerase MeSH D08.811.399.475.200.550 – mannose-6-phosphate isomerase MeSH D08.811.399.475.200.662 – neuroleukin MeSH D08.811.399.475.200.775 – triose-phosphate isomerase MeSH D08.811.399.475.400 – carbon-carbon double bond isomerases MeSH D08.811.399.475.400.700 – steroid isomerases MeSH D08.811.399.475.800 – sulfur-sulfur bond isomerases MeSH D08.811.399.475.800.550 – protein disulfide-isomerase MeSH D08.811.399.475.900 – thromboxane-a synthase
The city has hosted numerous major sporting events, including the inaugural AFC Asian Cup, the 2008 Summer Olympics equestrian events, the 2009 East Asian Games, the Rugby World Cup Sevens in 1997 and 2005, the 2005 World Squash Championships and 2025 World Grand Prix (snooker). The territory regularly hosts the Hong Kong Sevens, Hong Kong Marathon, Hong Kong Open (tennis), Hong Kong Tennis Classic and LIV Golf Hong Kong. Hong Kong represents itself separately from mainland China, with its own sports teams in international competitions. The territory has participated in almost every Summer Olympics since 1952 (with the exception of its support of the 1980 Summer Olympics boycott) and has earned nine medals. Lee Lai-shan won the territory's first Olympic gold medal at the 1996 Atlanta Olympics, and Cheung Ka Long won the second one in Tokyo 2020. Hong Kong athletes have won 126 medals at the Paralympic Games and 17 at the Commonwealth Games. Although they are no longer part of the Commonwealth of Nations, the city's last appearance was in 1994.
=== Risk factors === Family history and ancestry are factors that increase the risk of beta-thalassemia. Depending on family history, if a person's parents or grandparents had beta thalassemia major or intermedia, there is a 75% (3 out of 4) probability (see inheritance chart at top of page) of the mutated gene being inherited by an offspring. Even if a child does not have symptomatic beta thalassemia they can still be a carrier, leading to an increased risk in future generations of their offspring having beta-thalassemia. Beta thalassemia occurs most often in people of Mediterranean, Middle Eastern, Southern Asian, and African ancestry.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.